Article Sidebar

PDF
Date Published: 25/04/2025
Abstract Views: 355
Views PDF: 101
DOI: 10.58490/ctump.2025i86.3363
Issue
No. 86 (2025)
Section
Article
How to Cite
Le, T. H., Nguyen, V. C., Nguyen, T. T. H., & Nguyen, T. H. C. (2025). STUDY ON THE PATHOLOGICAL CHARACTERISTICS OF HORMONE RECEPTOR-POSITIVE BREAST CANCER. Cantho Journal of Medicine and Pharmacy, 86, 162-168. https://doi.org/10.58490/ctump.2025i86.3363

STUDY ON THE PATHOLOGICAL CHARACTERISTICS OF HORMONE RECEPTOR-POSITIVE BREAST CANCER

Thanh Huy Le1, , Van Cau Nguyen1, Tran Thuc Huan Nguyen1, Thi Hong Chuyen Nguyen1
1 Hue University of Medicine and Pharmacy, Hue University

Main Article Content

Abstract

 Background: Breast cancer is the most common malignant disease among women worldwide, with a high incidence in both developed and developing countries. Objective: To investigate the clinical characteristics, histopathological features and treatment outcomes of hormone receptorpositive breast cancer at Hue University of Medicine and Pharmacy Hospital. Material and methods: A retrospective case series study was conducted, combining patient follow-up, on 66 patients diagnosed with hormone receptor-positive breast cancer (ER+ or PR+) from January 2019 to June 2022. Data were collected from medical records and analyzed using SPSS 25.0 software, with a significance level set at p<0.05. Results: The average age of the sample was 53.6 ± 9.8 years, with 65.2% being postmenopausal. The most common tumor location was the upper outer quadrant (45.5%) and 48.5% of tumors were located in the left breast. The most frequent biological subtype was Luminal B Her2(-) (53.0%), and the majority of tumors were grade 2 (62.1%). Regarding treatment, 95.4% of patients underwent breast surgery with axillary dissection, and 90.9% received endocrine therapy (62.1% used AIs). The 3-year disease-free survival rate was 85%, and the overall survival rate was 86%. Conclusions: Hormone receptor-positive breast cancer predominantly affects middleaged and postmenopausal women, with a favorable prognosis. Endocrine and multimodal therapies significantly improve treatment outcomes and survival rates for these patients.

Keywords

Breast cancer, endocrine positive, clinical characteristics, biological subtypes

Article Details

References

1. Huỳnh Thị Thanh Giang, Nguyễn Hồng Hoa, Nguyễn Minh Tân và cộng sự. Nghiên cứu đặc điểm bệnh nhân ung thư vú giai đoạn sớm điều trị nội tiết tại bệnh viện quân y 175. Tạp Chí Y học Việt Nam. 2023. 526(1B). https://doi.org/10.51298/vmj.v526i1B.5427.
2. Nguyễn Văn Chủ, Nguyễn Tiến Quang. Đặc điểm giải phẫu bệnh của ung thư vú nhóm phân tử lòng ống. Tạp chí Y Dược lâm sàng 108. 2020. 15(3).
3. Elston, C. W., & Ellis, I. O. Pathological prognostic factors in breast cancer. Histopathology. 1991. 19(5), 403-410, doi:10.1111/j.1365-2559.1991.tb00229.x.
4. Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., Senn, H. J., & Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the
St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology : official journal of the European Society for Medical Oncology. 2011. 22(8), 1736–1747, https://doi.org/10.1093/annonc/mdr304.
5. Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H. J., & Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology : official journal of the European Society for Medical Oncology. 2013. 24(9), 2206–2223, https://doi.org/10.1093/annonc/mdt303.
6. Lê Hồng Quang, Nguyễn Văn Đức. Kết quả điều trị ung thư biểu mô tuyến vú thể nội ống tại bệnh viện K. Tạp Chí Y học Việt Nam. 2022. 514(2). https://doi.org/10.51298/vmj.v514i2.2639.
7. Ziyeh, S., Wong, L., & Basho, R. K. Advances in Endocrine Therapy for Hormone ReceptorPositive Advanced Breast Cancer. Current oncology reports. 2023. 25(7), 689–698. https://doi.org/10.1007/s11912-023-01393-6.
8. Dowsett M., et al. Meta-analysis of breast cancer outcomes in patients treated with aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology. 2010. 28(3), 509-518. doi:10.1200/JCO.2009.23.1274.
9. Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. 2015. 386(10001), 1341-1352. doi:10.1016/S0140-6736(15)61142-1.
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet. 1998. May 16, 351(9114), 1451-67.
11. GLOBOCAN. Global cancer statistics: incidence and mortality worldwide. World Health Organization. 2020.
12. Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., Runowicz, C. D., James, J. M., Ford, L. G., & Wolmark, N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 2005. 97(22), 1652–1662, https://doi.org/10.1093/jnci/dji372.
13. Jhaveri, K., & Marmé, F. Current and emerging treatment approaches for hormone receptorpositive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer treatment reviews. 2024. 123, 102670. https://doi.org/10.1016/j.ctrv.2023.102670.